<DOC>
	<DOCNO>NCT00984646</DOCNO>
	<brief_summary>The purpose study investigate scar-reducing property eight dos intradermal Prevascar ( IL-10 ) .</brief_summary>
	<brief_title>Investigation Into Scar Reduction Potential Prevascar ( Interleukin-10 )</brief_title>
	<detailed_description>Subjects randomise one two dose group , four concentration intradermal Prevascar . Subjects four 1cm incisional wound make inner aspect upper arm ( eight total ) , give four set anatomically pair wound sit per subject . Each subject act control one site wound pair randomly treat intradermal Prevascar treat Placebo ( vehicle ) Standard Care . Intradermal Prevascar administer 100μl per linear cm wound site prior wound Day 0 100μl per linear cm wind margin 24 hour later Day 1 . Group 1 subject receive dose 5 , 50 , 250 1000ng/100μl group 2 subject receive 25 , 125 , 500 2000ng/100μl . Subjects group also randomise two control subgroup receive either 100μl/linear cm intradermal placebo ( Subgroup 1 ) Standard Care alone ( Subgroup 2 ) control wound site . Subjects return follow-up Day 14 , Month 1 , Month 3 , Month 6 , Month 9 Month 12 .</detailed_description>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Male female subject , age 1885 year , give write informed consent Subjects BMI ( Quetelet 's index ) within permit weight/height2 range 1555kg/m2 Subjects , opinion Investigator , clinically acceptable result screen laboratory test perform within 28 day prior first trial administration Female subject childbearing potential use method ( ) contraception deem acceptable Investigator agree continue first month trial Subjects , direct question physical examination , reveal history evidence hypertrophic keloid scar Subjects tattoos previous scar within 3cm area incise trial Subjects AfroCaribbean descent , increase susceptibility hypertrophic keloid scar Subjects previous surgery area incise , conduct within 1 year first dose day Subjects history bleed disorder receive anticoagulant therapy Subjects , direct question physical examination , show evidence past present clinically significant disease may affect endpoint trial , e.g . coagulation disorder , diabetes , immuno mediate condition clinically significant skin disease allergies Subjects clinically significant skin disorder chronic currently active , Investigator consider adversely affect heal acute wound involve area examine trial Subjects clinically significant medical condition history would impair wound healing , include significant rheumatoid arthritis , chronic renal impairment ( significant age ) , significant hepatic impairment ( liver function test &gt; 3 time upper limit normal ) , congestive heart failure , active malignancy history malignancy within last 5 year , immunosuppression chemotherapy within last 12 month , history radiotherapy diabetes mellitus Subjects history hypersensitivity drug dressing use trial Subjects taking , take , investigational product participate clinical trial within 3 month prior first trial dose administration Subjects take regular , continuous , oral corticosteroid therapy Subjects undergoing investigation change management exist medical condition Subjects history drug abuse , test positive drug abuse ( cocaine , amphetamine , methamphetamine , opiates benzodiazepine ) screen period , explain intake legitimate prescribe overthecounter medication document medical condition Subjects , opinion Investigator , unlikely complete trial whatever reason Subjects receive immunosuppressive treatment Females pregnant lactating Subjects clinically significant neurological impairment disease Subjects active infection ( subject able participate trial infection pass rescreened )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Scar</keyword>
	<keyword>Wound-healing</keyword>
	<keyword>Prevascar</keyword>
	<keyword>Interleukin-10 ( IL-10 )</keyword>
	<keyword>Ilodecakin</keyword>
	<keyword>RN1003</keyword>
</DOC>